James Wason

James Wason

Professor of Biostatistics

Population Health Sciences Institute

Biography

Background

I am a statistician with interests in methods for improving the design and analysis of clinical trials. As well as working in methodology development I have a great interest in collaborating on real trials to apply new methods in practice.

I have been at Newcastle University since July 2017.

Areas of expertise

  • Biostatistics
  • Clinical trials
  • Novel trial design

Research

My research focuses on statistical methods for improved design and analysis of clinical trials. I am particularly interested in:

  1. Adaptive designs for clinical trials;
  2. Methods for incorporating biomarkers into clinical trials to stratify patients by treatment response;
  3. Improved methods for analysing composite endpoints, in particular ones with continuous components.

Scopus: Click here

Contact

FAQs

Q: How do you pronounce your surname?

A: It rhymes with Mason, like ‘Way-son’.

Publications

Quickly discover relevant content by filtering publications.
Fulvio Zaccagna, Mary A. McLean, James T. Grist, Joshua Kaggie, Richard Mair, Frank Riemer, Ramona Woitek, Andrew B. Gill, Surrin Deen, Charlie J. Daniels, Stephan Ursprung, Rolf F. Schulte, Kieren Allinson, Anita Chhabra, Marie-Christine Laurent, Matthew Locke, Amy Frary, Sarah Hilborne, Ilse Patterson, Bruno D. Carmo, Rhys Slough, Ian Wilkinson, Bristi Basu, James Wason, Jonathan H. Gillard, Tomasz Matys, Colin Watts, Stephen J. Price, Thomas Santarius, Martin J. Graves, Sarah Jefferies, Kevin M. Brindle, Ferdia A. Gallagher (2022). Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-$łess$sup$greater$13$łess$/sup$greater$C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study. Radiology: Imaging Cancer.

Cite DOI URL

Masatsugu Sakata, Rie Toyomoto, Kazufumi Yoshida, Yan Luo, Yukako Nakagami, Teruhisa Uwatoko, Tomonari Shimamoto, Aran Tajika, Hidemichi Suga, Hiroshi Ito, Michihisa Sumi, Takashi Muto, Masataka Ito, Hiroshi Ichikawa, Masaya Ikegawa, Nao Shiraishi, Takafumi Watanabe, Ethan Sahker, Yusuke Ogawa, Steven D Hollon, Linda M Collins, Edward R Watkins, James Wason, Hisashi Noma, Masaru Horikoshi, Taku Iwami, Toshi A Furukawa (2022). Components of smartphone cognitive-behavioural therapy for subthreshold depression among 1093 university students: a factorial trial. Evidence Based Mental Health.

Cite DOI URL

Shelley Dua, Monica Ruiz-Garcia, Simon Bond, James Dowey, Stephen R. Durham, Ian Kimber, Clare Mills, Graham Roberts, Isabel Skypala, James Wason, Pamela Ewan, Robert J. Boyle, Andrew Clark (2022). Effects of Exercise and Sleep Deprivation on Reaction Severity During Oral Peanut Challenge: A Randomized Controlled Trial. The Journal of Allergy and Clinical Immunology: In Practice.

Cite DOI URL

Aritra Mukherjee, James M. S. Wason, Michael J. Grayling (2022). When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay. European Journal of Cancer.

Cite DOI URL

Aritra Mukherjee, Michael J. Grayling, James M. S. Wason (2022). Adaptive Designs: Benefits and Cautions for Neurosurgery Trials. World Neurosurgery.

Cite DOI URL

Amanda D Busby, James Wason, Arthur G Pratt, Adam Young, John D Isaacs, Elena Nikiphorou (2022). The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data. Rheumatology.

Cite DOI URL

Haiyan Zheng, Thomas Jaki, James M. S. Wason (2022). Bayesian sample size determination using commensurate priors to leverage preexperimental data. Biometrics.

Cite DOI URL

Guy S. Taylor, Andy C. Shaw, Kieran Smith, James Wason, Timothy J. McDonald, Richard A. Oram, Emma Stevenson, James A. M. Shaw, Daniel J. West (2022). Capturing the real-world benefit of residual $p̆beta$-cell function during clinically important time-periods in established Type 1 diabetes. Diabetic Medicine.

Cite DOI URL

Vivien Li, Baptiste Leurent, Frederik Barkhof, Marie Braisher, Fay Cafferty, Olga Ciccarelli, Arman Eshaghi, Emma Gray, Jennifer M. Nicholas, Mahesh Parmar, Guy Peryer, Jenny Robertson, Nigel Stallard, James Wason, Jeremy Chataway (2022). Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis. Neurology.

Cite DOI URL

Michael J. Grayling, Martina McMenamin, Robert Chandler, Rakesh Heer, James M. S. Wason (2022). Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials. BMC Cancer.

Cite DOI URL

Michael J. Grayling, James M. S. Wason, Sofía S. Villar (2022). Response adaptive intervention allocation in stepped-wedge cluster randomized trials. Statistics in Medicine.

Cite DOI URL

Nina Wilson, Katie Biggs, Sarah Bowden, Julia Brown, Munyaradzi Dimairo, Laura Flight, Jamie Hall, Anna Hockaday, Thomas Jaki, Rachel Lowe, Caroline Murphy, Philip Pallmann, Mark A. Pilling, Claire Snowdon, Matthew R. Sydes, Sofía S. Villar, Christopher J. Weir, Jessica Welburn, Christina Yap, Rebecca Maier, Helen Hancock, James M. S. Wason (2021). Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. BMC Medicine.

Cite DOI URL

Marco Egle, Saima Hilal, A M Tuladhar, Lukas Pirpamer, Edith Hofer, Marco Duering, James Wason, Robin G Morris, Martin Dichgans, Reinhold Schmidt, Daniel Tozer, Christopher Chen, Frank-Erik de Leeuw, Hugh S Markus (2021). Prediction of dementia using diffusion tensor MRI measures: the OPTIMAL collaboration. Journal of Neurology, Neurosurgery & Psychiatry.

Cite DOI URL

Busby AD, Wason J, Pratt AG, Young A, Isaacs JD, Nikiphorou E (2021). Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?. Rheumatology 2021; DOI:10.1093/rheumatology/keab598.

DOI

Grayling MJ, Bigirumurame T, Cherlin S, Ouma L, Zheng H, Wason J (2021). Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential. BMC Rheumatol 2021; 5:21.

DOI

Cherlin S, Wason JMS (2021). Developing a predictive signature for two trial endpoints using the cross-validated risk scores method. Biostatistics 2021; DOI: 10.1093/biostatistics/kxaa055.

Collins A, Lendrem D, Wason J, Tarn J, Howard-Tripp N, Bodewes I, Versnel MA, Gottenberg JE, Seror R, Mariette X, Ng WF (2021). Revisiting the JOQUER trial: Stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatol Int 2021; 41:1593-1600.

DOI

Kunzmann K, Grayling MJ, Lee KM, Robertson DS, Rufibach K, Wason JMS (2021). A review of Bayesian perspectives on sample size derivation for confirmatory trials. Am Stat 2021; DOI:10.1080/00031305.2021.1901782.

Vergis N, Phillips R, Cornelius V, Katsarou A, Youngstein T, Cook L, Willicombe M, Pilay C, Shturova T, Almonte M, Charania A, Turner R, Kon OM, Cooke G, Thursz M, Cherlin S, Wason J, Milojkovic D, Innes AJ, Cooper N (2021). Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: A structured summary of a study protocol for a randomised controlled trial. Trials 2021; 22:270.

DOI

Ouma LO, Grayling MJ, Zheng H, Wason J (2021). Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. Pharm Stat 2021; doi:10.1002/pst.2119.

DOI

See all publications